Dr. Sznol Discusses Immunotherapy Combinations in RCC – OncLive
OncLive |
Dr. Sznol Discusses Immunotherapy Combinations in RCC
OncLive Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses immunotherapy combinations in renal cell carcinoma (RCC). Aside from the impressive results with ipilimumab (Yervoy) and nivolumab (Opdivo) … |
